GlassScriptPhysician profile
Matthew Michael Eganhouse
NPI 1265091334
$1,654.83
in general payments reported to CMS, 2019-2025
13 companies · $617 in 2025
The $617 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $258 · 2024: $780 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $285.74 | 2025 | Hemospray |
| Boston Scientific Corporation | $226.63 | 2023-2024 | Axios, Resolution 360 Clip, Captivator II |
| Janssen Scientific Affairs, LLC | $210.12 | 2023-2024 | Stelara, Tremfya |
| Erbe USA INC | $155.75 | 2023-2025 | Erbe Apc3, Vio3 |
| Lilly USA, LLC | $143.01 | 2024 | Omvoh |
| Steris Corporation | $141.55 | 2024 | |
| Phathom Pharmaceuticals, INC. | $107.31 | 2024 | Voquezna |
| Medtronic, INC. | $104.82 | 2024-2025 | Pillcam, Endoflip |
| Conmed Corporation | $92.42 | 2025 | Conmed Biliary, Conmed Dilation, Conmed Generators |
| Abbvie INC. | $87.30 | 2023-2025 | Mavyret |
| Olympus America INC. | $42.77 | 2025 | Gastrointestinal Videoscope, Endoclot Phs, Single Use Electrosurgical Hemostatic Forceps |
| Gilead Sciences, INC. | $29.58 | 2025 | |
| Mallinckrodt Hospital Products INC. | $27.83 | 2025 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Eganhouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.